Anlon Healthcare Ltd announced that its management will participate in the Bharat Connect Conference: Rising Stars 2026, organized by Arihant Capital. The virtual investor meet is scheduled for Tuesday, September 29, 2026, from 3:00 pm to 4:00 pm IST.

The company stated that no unpublished price sensitive information (UPSI) would be shared or discussed during the session. This disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency for market participants regarding upcoming corporate interactions.

Event Details

The participation is part of a broader engagement strategy with investors and analysts. The details of the scheduled interaction are outlined below:

The event is organized by Arihant Capital and serves as a platform for listed companies to communicate with the investment community. Anlon Healthcare noted that changes to the schedule may occur due to exigencies on the part of participants or the company.

Compliance and Disclosure

The intimation was filed with both BSE Limited and the National Stock Exchange of India Ltd. The company confirmed that this information is also available on its official website. The filing was signed by Punitkumar Rasadia, Managing Director, on September 24, 2026.

This announcement highlights the company's adherence to regulatory norms regarding the dissemination of information during investor conferences, ensuring that all market participants have equal access to publicly available information.

Anlon Healthcare shareholders approved a share swap to acquire stakes in Apiqo Organics and Bizotic Lifescience during the annual general meeting held on September 5, 2026. The company subsequently disclosed the finalized pricing mechanism for the associated preferential allotment, setting the issue price at ₹17.85 per equity share.

Pricing and Valuation Details

The company determined the floor price in accordance with Regulation 164 of the SEBI ICDR Regulations. The volume-weighted average price on the National Stock Exchange over the 90 trading days preceding the relevant date was ₹17.85, while the 10-day average stood at ₹14.99. Consequently, the higher figure of ₹17.85 was adopted as the floor price.

An independent registered valuer, CA Gaurang Agarwal, issued a revised valuation report dated September 1, 2026. The report determined the fair value of Anlon Healthcare’s equity shares at ₹17.85 per share. This alignment between the regulatory floor price and the independent fair value ensures compliance with Chapter V of the SEBI ICDR Regulations.

Allottee Disclosures

The disclosure identifies the ultimate beneficial owners for the proposed allottees under the preferential issue. Key entities include Unicorn Fund, controlled by Nisarg Prafulbhai Thakkar, and various Hindu Undivided Families (HUFs) such as Jignesh C Parekh HUF and Piyush Shah HUF. Corporate allottees include Mars Forge Private Limited and Vedant Engitech and Infrastructure Private Limited.

Regulatory Compliance

The company addressed observations from both the BSE and NSE regarding the initial AGM notice and corrigendum. A certificate from M/s. K.P. Ghelani & Associates, Company Secretaries, confirms that the preferential issue adheres to SEBI ICDR requirements. This disclosure supplements the AGM notice and corrigendum previously circulated to shareholders.